Study Details: 15 min Online Survey Compensation $25 Now accepting Residents from ALL Countries!! * Companies have finally realized the REAL EXPERTS are the Patients and Caregivers! * Better products, services, and treatments, Start with Better Research. They need YOUR input and are willing to pay $100 an hour for it! Signup Today and let YOUR Voice be heard! Why …
Significant New Findings about Breast and Ovarian Cancer in Patients from the Caribbean
By: University of Miami Health System, Miller School of Medicine From: newswise.com Judith Hurley, M.D., an oncologist and researcher at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, has been studying racial disparities in breast cancer rates since 2002. After Dr. Hurley noticed that many of her Bahamian breast cancer patients were unusually young, she …
Rare Patient Voice: Ovarian Cancer Patients
Study Details: 2 day Online Bulletin Board Compensation $100 Please sign up at the link below for more information or to see if you qualify. https://rarepatientvoice.com/LetLifeHappen/ Why Sign up with Rare Patient Voice? Who knows better than you about your journey and experiences? We connect you with researchers who are developing products and services which can help you and others …
Popular breast cancer drugs don’t work the way we thought they did
By: Lisa Marshall From: colorado.edu Some of the most commonly used drugs for treating hereditary breast and ovarian cancers may not work the way we thought they did, according to new CU Boulder research. The paper, published Feb. 2 in the journal Nature Communications, sheds new light on how they do work and could open the door to new next-generation medications …
Rare Patient Voice: Ovarian Cancer Patients
Study Details: 15 min Online Survey Compensation $25 Please sign up at the link below for more information or to see if you qualify. https://rarepatientvoice.com/LetLifeHappen/ Why Sign up with Rare Patient Voice? Who knows better than you about your journey and experiences? We connect you with researchers who are developing products and services which can help you and others with …
Bard1 Life Sciences (ASX:BD1) reveals tech’s efficiency in detecting breast cancer
By: Samantha Goerling From: themarketherald.com.au Australian diagnostics company Bard1 Life Sciences (BD1) has revealed its SubB2M technology can detect all stages of breast cancer from a blood sample. Research completed by the Griffith University’s Institute for Glycomics found the technology could detect the cancer with 100 per cent specificity and 95 per cent sensitivity. “A non-invasive, accurate and reliable blood test …
Rare Patient Voice: Ovarian and Fallopian Tube Cancer, Age 25-75, Diagnosed 2016-2021
Study Details: 60 min Web-Assisted Phone Interview Compensation $100 Please sign up at the link below for more information or to see if you qualify. https://rarepatientvoice.com/LetLifeHappen/ Why Sign up with Rare Patient Voice? Who knows better than you about your journey and experiences? We connect you with researchers who are developing products and services which can help you and others …
Rare Patient Voice: Ovarian Cancer Patients and Caregivers (Diagnosed in the last 18 months)
Study Details: 60 min Web-Assisted Phone Interview Compensation $125 Please sign up at the link below for more information or to see if you qualify. https://rarepatientvoice.com/LetLifeHappen/ Why Sign up with Rare Patient Voice? Who knows better than you about your journey and experiences? We connect you with researchers who are developing products and services which can help you and others …
Research KSQ boosts PARP inhibition in animal models of ovarian and breast cancers with USP1 inhibitor
By: Arlene Weintraub From: fiercebiotech.com PARP inhibitors like Lynparza from Merck and AstraZeneca have been effective in some patients with ovarian and breast cancers, but many develop resistance to the drugs, and some people don’t respond at all. KSQ Therapeutics hopes to provide hope for those patients with a first-in-class drug that may be able to boost Lynparza’s effectiveness when …
Optimal Sequencing Remains a Hurdle in Ovarian Cancer Treatment
By: Brittany Lovely From: onclive.com The surge of treatment options for patients with ovarian cancer poses a daunting challenge as answers for optimal sequencing continue to elude clinicians. Bevacizumab (Avastin) continues to hold the most utility in this disease setting, but the addition of PARP inhibitors, and immunotherapy raises the question of how to best deliver efficient regimens to patients. …